Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile.

Am J Cardiovasc Drugs · 2026 · PMC13102893 · PMID 41686423

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Secondary Outcomes Safety Outcomes Adverse events appeared to be seen more in the cimlanod group (RR = 1.51; 95% CI 0.94–2.44; p = 0.073; I 2 = 71.4%; Supplementary Figure 2C) but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.